Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBP-426
- Development stage
- Phase 2
- Lead developer
- Mebiopharm
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
MBP-426 is a transferrin-conjugated nanoparticle formulation of oxaliplatin, a platinum-based chemotherapy drug. The formulation works through a dual mode of action: the nanoparticle delivery system extends circulation time, while the transferrin conjugation specifically targets transferrin receptors which are overexpressed on many cancer cells. This targeted delivery approach aims to improve both the safety and efficacy of oxaliplatin therapy compared to the conventional drug.
- Other names
- Transferrin-conjugated liposomal oxaliplatinTf-targeted liposomal oxaliplatin
02
Targets
TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on MBP-426.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBP-426.